Beykoz University, Vocational School, Department of Medical Services and Techniques, Beykoz, Istanbul, Turkey.
V. Akhundov National Scientific Research Medical Prophylactic Institute, Baku, Azerbaijan.
J Vector Borne Dis. 2023 Apr-Jun;60(2):125-141. doi: 10.4103/0972-9062.361179.
Leishmaniasis is a parasitic disease with different clinical forms caused by protozoan parasites of the genus Leishmania and transmitted by the bite of an infected female sandfly. According to the World Health Organization (WHO), it is the second most common parasitic disease after malaria and it is known that approximately 350 million people are at risk. The disease manifests itself in different clinical forms. In addition to asymptomatic cases, cutaneous leishmaniasis (CL), which creates large lesions on the skin, and visceral leishmaniasis (VL), which causes death if not treated, especially affecting the abdominal organs, are two important clinical forms. When the studies were examined, it was seen that a clinically used vaccine against any form of human leishmaniasis has not been developed yet. In some studies, it was stated that the lack of appropriate adjuvant was responsible for the failure to develop an effective Leishmania vaccine. We can say that strong adjuvants are needed to achieve successful vaccines. In this article, adjuvants and adjuvant candidates used in vaccine studies against leishmaniasis are discussed.
利什曼病是一种寄生虫病，由利什曼原虫属的原生动物寄生虫引起，通过受感染的雌性沙蝇叮咬传播。根据世界卫生组织（WHO）的数据，它是仅次于疟疾的第二大常见寄生虫病，据了解，约有 3.5 亿人面临风险。该疾病表现出不同的临床形式。除了无症状病例外，皮肤利什曼病（CL）会在皮肤上形成大的病变，内脏利什曼病（VL）如果不治疗会导致死亡，尤其是影响腹部器官，是两种重要的临床形式。在研究中发现，目前尚未开发出针对任何形式人类利什曼病的临床应用疫苗。在一些研究中，缺乏适当的佐剂被认为是未能开发出有效利什曼病疫苗的原因。我们可以说，需要强有力的佐剂才能实现成功的疫苗接种。本文讨论了用于利什曼病疫苗研究的佐剂和佐剂候选物。
